Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus HYDRO RIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus HYDRO RIDE.
HYDRO-D vs HYDRO-RIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
25-100 mg orally once daily in the morning.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Terminal half-life 4-6 hours (prolonged in renal impairment).
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic